Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Targeting Treatment: Selecting Optimal Therapy for Vulnerable Patients

Premiere Date: Tuesday, February 22, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, February 22, 2023

Faculty


John P. Leonard, MDJohn P. Leonard, MD (Moderator)
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chairman, Department of Medicine
Weill Cornell Medicine and New York-Presbyterian Hospital
New York, NY

Kami J. Maddocks, MDKami J. Maddocks, MD 
Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH

Statement of Need

Follicular lymphoma (FL) is characterized by repeated remissions and relapses. Due to the older median age at diagnosis (63 years) and indolent disease course, it is not uncommon to encounter septua- and octogenarians in practice. Health care professionals (HCPs) must understand the impact of aging therapeutic decisions, while minimizing toxicity and maintaining quality of life (QoL).

This final installment in a 3-part CME Outfitters’ series on follicular lymphoma will assess the needs of older patients with FL when creating treatment plans. Join Dr. Maddocks and Dr. Leonard as they discuss the impacts of aging on treatment selection and preferred treatments for older patients with FL.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Evaluate therapy options to select the most optimal treatment for older patients with relapsed/refractory FL.

Financial Support

Supported by an educational grant from Genentech, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in hematology, oncology, and/or geriatrics

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Leonard reports the following financial relationships:

Consultant: AbbVie Inc.; ADC Therapeutics; Bayer; Bristol Myers Squibb; Celgene/Celgene Corporation; Eisai Inc.; Epizyme, Inc.; Gilead Sciences, Inc./Kite Pharma; Incyte; Janssen Pharmaceuticals, Inc.; Karyopharm; Miltenyi Biotec; Mustang Bio; Sandoz; Second Genome Therapeutics; and Sutro Biopharma, Inc.

Dr. Maddocks reports the following financial relationships:

Consultant: Acerta Pharma; ADC Therapeutics; AstraZeneca; Bristol Meyer Squibb Company; Celgene Corporation; Epizyme, Inc.; Genentech, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kite; Lilly; MorphoSys US Inc.; and Seattle Genetics, Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
  • David Modrak, PhD (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)


  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    SN-160-022222-31

    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download